Carl Zeiss Meditec Stock Performance
| CZMWF Stock | USD 68.73 7.73 12.67% |
On a scale of 0 to 100, Carl Zeiss holds a performance score of 12. The firm shows a Beta (market volatility) of 0.85, which signifies possible diversification benefits within a given portfolio. Carl Zeiss returns are very sensitive to returns on the market. As the market goes up or down, Carl Zeiss is expected to follow. Please check Carl Zeiss' maximum drawdown, as well as the relationship between the expected short fall and day median price , to make a quick decision on whether Carl Zeiss' price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Carl Zeiss Meditec are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite nearly weak basic indicators, Carl Zeiss reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 7.4 M | |
| Total Cashflows From Investing Activities | -148.9 M |
Carl |
Carl Zeiss Relative Risk vs. Return Landscape
If you would invest 5,046 in Carl Zeiss Meditec on December 18, 2024 and sell it today you would earn a total of 1,827 from holding Carl Zeiss Meditec or generate 36.21% return on investment over 90 days. Carl Zeiss Meditec is currently producing 0.5974% returns and takes up 3.8744% volatility of returns over 90 trading days. Put another way, 34% of traded pink sheets are less volatile than Carl, and 89% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Carl Zeiss Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Carl Zeiss' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Carl Zeiss Meditec, and traders can use it to determine the average amount a Carl Zeiss' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1542
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CZMWF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.87 actual daily | 34 66% of assets are more volatile |
Expected Return
| 0.6 actual daily | 11 89% of assets have higher returns |
Risk-Adjusted Return
| 0.15 actual daily | 12 88% of assets perform better |
Based on monthly moving average Carl Zeiss is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Carl Zeiss by adding it to a well-diversified portfolio.
Carl Zeiss Fundamentals Growth
Carl Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Carl Zeiss, and Carl Zeiss fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Carl Pink Sheet performance.
| Return On Equity | 0.16 | |||
| Return On Asset | 0.0955 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.21 % | |||
| Current Valuation | 12.07 B | |||
| Shares Outstanding | 89.44 M | |||
| Price To Earning | 75.63 X | |||
| Price To Book | 6.17 X | |||
| Price To Sales | 6.34 X | |||
| Revenue | 1.9 B | |||
| EBITDA | 419.49 M | |||
| Cash And Equivalents | 8.4 M | |||
| Cash Per Share | 0.09 X | |||
| Total Debt | 120.05 M | |||
| Debt To Equity | 0.07 % | |||
| Book Value Per Share | 22.53 X | |||
| Cash Flow From Operations | 188.2 M | |||
| Earnings Per Share | 2.93 X | |||
| Total Asset | 2.4 B | |||
| Retained Earnings | 458 M | |||
| Current Asset | 859 M | |||
| Current Liabilities | 286 M | |||
About Carl Zeiss Performance
By analyzing Carl Zeiss' fundamental ratios, stakeholders can gain valuable insights into Carl Zeiss' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Carl Zeiss has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Carl Zeiss has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, the United States, Asia, and internationally. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss operates under Medical Instruments Supplies classification in the United States and is traded on OTC Exchange. It employs 3531 people.Things to note about Carl Zeiss Meditec performance evaluation
Checking the ongoing alerts about Carl Zeiss for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Carl Zeiss Meditec help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Carl Zeiss Meditec appears to be risky and price may revert if volatility continues | |
| About 59.0% of the company shares are held by company insiders |
- Analyzing Carl Zeiss' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Carl Zeiss' stock is overvalued or undervalued compared to its peers.
- Examining Carl Zeiss' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Carl Zeiss' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Carl Zeiss' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Carl Zeiss' pink sheet. These opinions can provide insight into Carl Zeiss' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Carl Pink Sheet analysis
When running Carl Zeiss' price analysis, check to measure Carl Zeiss' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Carl Zeiss is operating at the current time. Most of Carl Zeiss' value examination focuses on studying past and present price action to predict the probability of Carl Zeiss' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Carl Zeiss' price. Additionally, you may evaluate how the addition of Carl Zeiss to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |